Renovascular hypertension: to stent or not to stent?

Affiliations

• ¹ From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK (P.B.M., A.F.D.); Lady Davis Institute for Medical Research and Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, PQ, Canada (E.L.S.); Director's Research Group, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (G.L.J.); Center for Epidemiological Studies and Clinical Trials, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai, China (J.-G.W.); Department of Cardiology, Ghent University, Ghent, Belgium (M.D.B.); and Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium and VitaK Research and Development, Maastricht University, Maastricht, The Netherlands (J.A.S.). patrick.mark@glasgow.ac.uk.
• ² From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK (P.B.M., A.F.D.); Lady Davis Institute for Medical Research and Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, PQ, Canada (E.L.S.); Director's Research Group, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (G.L.J.); Center for Epidemiological Studies and Clinical Trials, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai, China (J.-G.W.); Department of Cardiology, Ghent University, Ghent, Belgium (M.D.B.); and Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium and VitaK Research and Development, Maastricht University, Maastricht, The Netherlands (J.A.S.).